#USA #New York #Class Action #The Gross Law Firm #ADMA Biologics

Important Update for ADMA Biologics Shareholders

The Gross Law Firm has issued a significant notice for the shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA), informing them of a securities class action lawsuit that could have implications for their investments. If you purchased shares of ADMA Biologics between August 9, 2024, and March 25, 2026, this is an important message for you.

Allegations Against ADMA Biologics

The allegations laid out in the complaint are serious and suggest a breach of transparency and ethical conduct by ADMA Biologics. Some key points include:
1. Undisclosed Related Party Transactions: It is alleged that ADMA engaged in transactions with related parties without proper disclosure, which is a red flag for investors seeking transparency.
2. Use of Channel Stuffing: The company is accused of utilizing channel stuffing—a strategy to inflate sales figures by pushing more products into the distribution channel than the market can absorb—to create a misleading picture of its revenue flows.
3. Insufficient Internal Controls: Finally, it is claimed that ADMA Biologics failed to maintain adequate internal controls, leading to statements made by the company about its operations being materially false or misleading.

These allegations may have contributed to an artificial inflation of the company’s stock price, potentially impacting many investors who bought shares during the stated class period.

Next Steps for Shareholders

Shareholders are encouraged to take action promptly. Here’s a brief guide on what to do:

• - Register Your Information: It is imperative to register your details to participate in the class action lawsuit. This registration will enroll you in a monitoring platform that provides updates as the case progresses.
• - Lead Plaintiff Opportunity: Investors wishing to take an active role can seek to become the lead plaintiff. However, it must be noted that this is not required to participate in any potential recovery.
• - Deadline Awareness: The deadline to register as a lead plaintiff is August 10, 2026. Act quickly to secure your position in this class action.

The Role of The Gross Law Firm

The Gross Law Firm is well-established in handling class action lawsuits and is dedicated to safeguarding the rights of investors who have sustained losses due to fraudulent practices or misleading statements by companies. They work tirelessly to ensure that firms adhere to ethical business practices and corporate responsibility.

If you are an ADMA Biologics investor and wish to know your rights or file a claim, you can reach out to them at:

• - Contact Information: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Phone: (646) 453-8903
• - Email: [email protected]

Conclusion

As an investor in ADMA Biologics, it is crucial to stay informed about the developments regarding this potential class action lawsuit. Whether you decide to register your claim, become a lead plaintiff, or simply monitor the case, being proactive can help protect your investment interests in the wake of these serious allegations. Be sure to visit the registration link provided and take the next steps soon, as time is of the essence in this legal process.